Zenas BioPharma Business Summary

Zenas BioPharma, Inc. (ZBIO) is a clinical-stage global biopharmaceutical company focused on the development and commercialization of transformative therapies for autoimmune and rare diseases. The company generates revenue primarily through strategic licensing agreements, milestone payments, and collaborative partnerships, such as its worldwide rights acquisition for its lead asset from Xencor. Its business segments are centered on its late-stage immunology pipeline, headlined by obexelimab—a bifunctional monoclonal antibody targeting CD19 and FcγRIIb—and orelabrutinib, a CNS-penetrant BTK inhibitor. As of February 2026, Zenas is transitioning toward a commercial-stage entity with a planned Biologics License Application (BLA) for obexelimab in IgG4-Related Disease (IgG4-RD) scheduled for Q2 2026. Within the competitive landscape, Zenas competes directly with Cabaletta Bio, Alumis, and Celldex Therapeutics, positioning itself as a specialist in non-depleting B-cell inhibition to offer a more tolerable safety profile compared to traditional B-cell depleting therapies. Zenas was founded by Leon "Lonnie" Moulder, Jr., who serves as the current Chief Executive Officer and Chairman of the Board. Moulder brings a distinguished pedigree as the former CEO of TESARO (acquired by GSK for $5.1 billion) and MGI PHARMA (acquired by Eisai for $3.9 billion). The leadership team includes Jennifer Fox as Chief Business Officer and CFO, previously a Managing Director at Citi and CFO of Nuvation Bio, and Dr. Tanya Fischer as Head of R&D and Chief Medical Officer, formerly of Biohaven and Bristol Myers Squibb. The company’s strategic direction is supported by a robust board and a high-profile investor base including New Enterprise Associates (NEA), Longitude Capital, Enavate Sciences, and Fairmount Funds. This veteran executive suite leverages deep expertise in oncology and immunology to navigate the complex regulatory pathways for its expanding portfolio of franchise molecules.